VC-backed Tandem Diabetes Care prices IPO – Fortune

According to Fortune, Tandem Diabetes Care has priced its IPO of 7.14 million shares between $13 and $15 per share. The company plans on listing its stock on the NASDAQ under the ticker symbol “TNDM.”  BoA Merrill Lynch and Piper Jaffray are serving as lead underwriters.  Based in San Diego, Tandem Diabetes Care is a provider of medical devices that treat diabetes. The firm is backed by Delphi Ventures, Domain Associates, TPG Biotechnology Partners, HLM Venture Partners and Kearny Venture Partners.